Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline.
about
Effects of beta-blockers on heart failure with preserved ejection fraction: a meta-analysisPatterns of weight change preceding hospitalization for heart failureDiastolic dysfunction and heart failure with a preserved ejection fraction: Relevance in critical illness and anaesthesiaN-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF).Heart failure and preserved left ventricular function: long term clinical outcome.Hip fractures and heart failure: findings from the Cardiovascular Health Study.Trajectories of life-space mobility after hospitalizationThe heart failure epidemic.Left ventricular dysfunction as a risk factor for cardiovascular and noncardiovascular hospitalizations in African AmericansCorrelation of Normal Diastolic Cardiac Function With VO in the Metabolic Syndrome.Left atrial function predicts heart failure hospitalization in subjects with preserved ejection fraction and coronary heart disease: longitudinal data from the Heart and Soul StudySerum 25-hydroxyvitamin D concentration is associated with functional capacity in older adults with heart failure.Heart failure--concepts and significance. Birth of a prognostic modelNitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial: rationale and designNew potential determinants of disability in aged persons with myocardial infarction: results from the KORINNA-studyManagement of heart failure with preserved ejection fraction in a local public hospital in Hong Kong.Heart failure with preserved left ventricular systolic function: a hospital cohort studyCare in the last year of life for community patients with heart failure.Left ventricular diastolic dysfunction in nonhuman primate model of dysmetabolism and diabetesPrognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.Prognostic Factors for Survival at 6-Month Follow-up of Hospitalized Patients with Decompensated Congestive Heart Failure.Role of echocardiography in the contemporary management of chronic heart failure.The Relationship between Perceived Life Changes and Mental Health in Family Caregivers of Patients with Heart Failure who Referred to Rajaei Cardiovascular Medical and Research Center, Tehran.Acutely decompensated congestive heart failure: new therapies for an old problem.Are myocardial fibrosis and diastolic dysfunction reversible in hypertensive heart disease?Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction.Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction.Early pharmacological treatment of acute heart failure syndromes: a systematic review of clinical trials.Dramatic reversal of derangements in muscle metabolism and left ventricular function after bariatric surgeryPattern of heart failure in Abuja, Nigeria: an echocardiographic study.Association of diastolic dysfunction and outcomes in ambulatory older adults with chronic heart failureDiastolic heart failure: a concise review.Recommendation of low-salt diet and short-term outcomes in heart failure with preserved systolic function.Objectively measured, but not self-reported, medication adherence independently predicts event-free survival in patients with heart failure.Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis.Heart failure in women: epidemiology, biology and treatment.Therapeutic interventions for heart failure with preserved ejection fraction: A summary of current evidence.Mortality in heart failure patients.Pharmacologic management of heart failure with preserved ejection fraction.
P2860
Q21132299-3731DDE8-AAD6-4955-AF49-D6EDA29D27F5Q24628173-69358EE4-44AE-4FD4-A80C-EEEA35DF019BQ30450624-642726BB-2F82-471D-9D56-1493DF1968FDQ30908647-FCFDAF17-4E16-493E-A46D-FDFADAE5517DQ31075676-F3A89293-796A-4C39-8285-550843C25F1AQ33568103-C7864BEA-B7D0-424B-93D2-605A10DA1F25Q33576150-8C2715A4-533B-4F68-A2E6-CA3AB3EF150EQ33858952-3EE4A2AD-2A97-4C92-A1DE-2506CD881329Q34125692-8C022D94-B8FF-4BA0-A733-48948D07174CQ34153840-93AB3778-ECC9-420D-9C7A-27181CD9167FQ34155579-BD0C44F3-091E-434B-ABE8-490BC2D0800DQ34385578-A306E0D3-03C6-4FD8-A98E-1A05A0F17C9DQ34481280-ADE8B758-303E-4D7C-ADA6-5AE157BA2E53Q35005829-DFE99C3A-7166-4239-8D45-024F21FA7AD7Q35124663-7D0A99BB-B5B5-418E-836C-4CB29DF5D52EQ35190912-E746C98B-32CA-4DCD-9E15-0AFF52CCDA85Q35584442-1E79B9FD-2B8D-498E-B309-9EF7CFB61722Q35629821-C150FBA5-4782-4BD1-8635-A3E74F8818FBQ35827889-557DB005-B0B2-4E08-A0D1-C03335C17135Q35921040-C7C82CAD-E0B7-4095-9760-F416B8535D1AQ35945193-4AC994DE-7350-4E16-A644-CFE2EF91D104Q36050476-1B6893EF-27FC-4D03-969A-6203046C317AQ36114943-E6421833-C048-4895-8A56-0B09A0950D3BQ36266039-90447E2B-3202-45F4-9A9F-191540B22CF3Q36332221-7589B2D7-5242-48BB-9D40-1E4270FBF5CEQ36393927-42024DD3-4EDD-4236-9815-1341901CA8F7Q36459987-C962A2CA-D377-4B1B-BB2A-17132A55E256Q36799331-15A8DC5F-E1E0-46A6-84AC-8AC040F02278Q37018348-A22EC354-50CD-4796-86D5-4E7AFFA4EB68Q37040296-84CFAF9B-95A5-4E82-AF79-B47FA697CE48Q37066519-688C2CE4-39B7-47C1-B060-F4B211B3087DQ37108558-13A7D52C-A76B-45D8-8F76-8EE36F4BD213Q37160768-D7D04A5D-59FF-4E93-8D3D-2144A4C6736BQ37362262-ED38208C-B81C-4820-B256-ECFDDD5572E4Q37417004-4A45B5B2-FBED-46E7-8F7A-C3591EB8474FQ37572119-7DD37C06-2845-4984-9EF7-B14C2FB11C60Q37585303-01DD21B2-E16F-4A50-8CEC-6B0D793F5A95Q37603728-8BB02475-0B1C-4CAC-AE4C-3E042DAC0AF8Q37680497-D73DCC70-3C2B-4A3E-9A93-10F04B89B06CQ37811698-8C986E09-1F96-43B1-98BF-9C81B50D29D7
P2860
Outcomes in heart failure patients with preserved ejection fraction: mortality, readmission, and functional decline.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Outcomes in heart failure pati ...... ssion, and functional decline.
@en
Outcomes in heart failure pati ...... ssion, and functional decline.
@nl
type
label
Outcomes in heart failure pati ...... ssion, and functional decline.
@en
Outcomes in heart failure pati ...... ssion, and functional decline.
@nl
prefLabel
Outcomes in heart failure pati ...... ssion, and functional decline.
@en
Outcomes in heart failure pati ...... ssion, and functional decline.
@nl
P50
P1476
Outcomes in heart failure pati ...... ssion, and functional decline.
@en
P2093
Grace L Smith
Viola Vaccarino
P304
P356
10.1016/S0735-1097(03)00185-2
P407
P577
2003-05-01T00:00:00Z